林业发展局可能很快批准口服肥胖症药品,提供类似效果的无针选择。 FDA likely to approve oral obesity drugs soon, offering needle-free option with similar effectiveness.

现在只能注射的流行肥胖药物口服版本预计将在未来几个月获得FDA的批准, 为患者提供更方便的替代品. Oral versions of popular obesity medications, currently only available as injections, are expected to receive FDA approval in the coming months, offering a more convenient alternative for patients. 这些基于司美格鲁肽和替泽帕肽等活性成分的药丸形式，旨在提高针头的依从性和可及性，尤其适合厌恶针头的人。 These pill forms, based on active ingredients like semaglutide and tirzepatide, aim to improve adherence and access, especially for those averse to needles. 虽然早期临床数据显示了类似的体重下降效果,但长期安全和现实世界成果仍在评价中。 While early clinical data shows similar weight loss effectiveness, long-term safety and real-world outcomes are still under evaluation. 成本和保险覆盖面仍然不确定,但这一转变可以大大扩大40%以上美国成人肥胖症患者的治疗选择。 Cost and insurance coverage remain uncertain, but the shift could significantly expand treatment options for the more than 40% of American adults living with obesity.